Evidence supporting the use of: Tetrahydrocannabinol
For the body system: Eyes

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis, has been studied for its effects on intraocular pressure (IOP), which is a major risk factor in glaucoma, a disease that can lead to vision loss. Research dating back to the 1970s demonstrated that THC can lower IOP in both healthy individuals and those with glaucoma. The mechanism is believed to involve cannabinoid receptors in ocular tissues, which modulate aqueous humor production and outflow. However, the effects of THC on IOP are short-lived, typically lasting only 3-4 hours, requiring frequent dosing that can lead to significant systemic side effects, including psychoactivity, cardiovascular effects, and cognitive impairment.

While the IOP-lowering properties of THC are scientifically validated, major ophthalmological bodies, such as the American Academy of Ophthalmology, do not recommend THC or cannabis as a primary or adjunct treatment for glaucoma due to the short duration of action and side effect profile. Instead, longer-acting and safer medications are preferred. There is no substantial evidence that THC improves vision or supports eye health outside of its temporary impact on IOP. Thus, while there is scientific basis for THC affecting the eye, especially in the context of glaucoma, the clinical utility remains limited and is not recommended as standard therapy.

More about Tetrahydrocannabinol
More about Eyes

Other body systems supported by Tetrahydrocannabinol

Brain
Digestive System
Eyes
Gastrointestinal Tract
Nerves

Products containing Tetrahydrocannabinol

We currently have no products on Vitabase that contain this ingredient.